Morning Depression in Elderly Patients
Screen for depression using two simple questions about mood and anhedonia, then initiate treatment with either cognitive behavioral therapy (CBT) or an SSRI antidepressant as monotherapy for moderate-to-severe depression, with CBT preferred for mild depression. 1, 2
Initial Evaluation: The "Mind" Domain
Start by assessing cognitive and psychological health using the Geriatric 5Ms framework, as cognitive impairment fundamentally changes how you evaluate and manage all other aspects of care 3. Ask these two screening questions:
- "Over the past 2 weeks, have you felt down, depressed, or hopeless?"
- "Over the past 2 weeks, have you felt little interest or pleasure in doing things?" 1
These questions are as effective as formal screening instruments. If positive, proceed to a full diagnostic interview using DSM criteria to confirm major depressive disorder, dysthymia, or subsyndromal depression 1.
Key Assessment Points
Look specifically for:
- Concurrent medical conditions (hypothyroidism, cardiovascular disease, neurological disorders) that may contribute to or complicate depression 2, 4
- Cognitive impairment - depression presents differently and responds less predictably to treatment when dementia is present 2
- Medication review - identify drugs that may cause or worsen depression (beta-blockers, corticosteroids, benzodiazepines) 3, 4
- Sleep disturbances - these significantly influence treatment decisions 5
- Polypharmacy risks - use STOPP/START criteria to identify potentially inappropriate medications 2
Treatment Algorithm
For Mild Depression
Initiate CBT as monotherapy 6. This avoids medication risks in a population already on multiple drugs and provides comparable efficacy for mild symptoms.
For Moderate-to-Severe Depression
Choose between three evidence-based options 6:
CBT monotherapy - preferred if patient is frail, has multiple drug interactions, or prefers non-pharmacologic treatment 2, 7
SSRI monotherapy - among SSRIs, citalopram and sertraline receive the highest expert ratings for efficacy and tolerability in elderly patients 4. Start at lower doses than younger adults but titrate to the same therapeutic doses most patients need 2.
Combination therapy (CBT + SSRI) - for more severe presentations 6
Critical Medication Considerations
Be cautious with SSRIs in patients over 65 due to increased upper gastrointestinal bleeding risk, which rises further with concurrent NSAID or aspirin use 1. The bleeding risk increases with medications featuring moderate-to-high serotonin reuptake inhibition 1.
Avoid tricyclic antidepressants and MAO inhibitors - these are less favored due to poor tolerability and safety profiles in elderly patients 5.
For psychotic depression, combine an SSRI with an atypical antipsychotic, or consider electroconvulsive therapy as first-line treatment 4.
Common Pitfalls
Do not use antidepressants for depression in patients with dementia - high-quality evidence does not support this practice 2. Focus on non-pharmacologic interventions instead.
Do not assume depression is "normal aging" - while medical illness, cognitive decline, bereavement, and institutional placement are associated with depressive symptoms, these are risk factors, not diagnostic criteria 1.
Do not undertreate - many elderly patients require the same antidepressant doses as younger adults 2. Start low but titrate adequately.
Duration of Treatment
Continue antidepressant medication for:
- At least 1 year after a single severe episode
- 1-3 years after two episodes
- Longer than 3 years after three or more episodes 4
Monitor closely during any tapering period as discontinuation carries relapse risk 2.
Adjunctive Interventions
Include psychoeducation, family counseling, and visiting nurse services as appropriate 4. Exercise therapy may also be effective for mild-moderate depression 2, 7. For treatment-resistant cases in appropriate candidates, consider electroconvulsive therapy or transcranial magnetic stimulation 7.
Note the limitation: Psychotherapy efficacy is reduced in very old patients (>75 years) and those with cognitive impairment 7, making medication relatively more important in these subgroups despite the increased adverse event risks.